Ineffectiveness of lipid-lowering therapy in primary care

British Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2005, Pages 456-463

  Van Ganse, E ^a,f   Souchet, T ^b   Laforest, L ^a   Moulin, P ^a   Bertrand, M ^c   Le Jeunne, P ^d   Travier, N ^a   Yin, D ^b   Alemao, E ^b   De Pouvourville, G ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d BKL   (France)

^e INSERM   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Coronary heart disease; Dyslipidaemia; Effectiveness; Lipid lowering agents

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT FAILURE;

ADULT; AGED; ANTILIPEMIC AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; FAMILY PRACTICE; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINES; PRIMARY PREVENTION; RISK FACTORS; TREATMENT FAILURE;

EID: 20244377383     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02266.x     Document Type: Article

References (23)

1. Selke B, Laurent P. Maladies Cardio-Vasculaires. Impact Medico-Economique de la Prise en Charge Médicamenteuse par Hypolipemiants a partie d'une Revue de la Littérature. Rapport au Syndicat National de L'Industrie Pharmaceutique. 1999 (CRESGE) Lille, France.
2. Stein EA. Managing dyslipidaemia in the high-risk patient. Am J Cardiol 2002; 89(Suppl): 50C-57C.
3. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
4. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000; 160: 459-67.
5. EUROASPIRE II, Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE 11 Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
6. Van Ganse E. Use of computerized data in pharmacoepidemiology. Therapie 2000; 55: 123-6.
7. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
8. Agence Française de Sécurité Sanitaire des Produits de Santé. La prise en charge thérapeutique du patient dyslipidémique - Recommandations; September 2000. Afsapps, Saint Denis, France.
9. Agence Nationale pour le Développement et l'Evaluation Médicale (ANDEM). Hypolipidémiants Concours Méd 1996; 41: 58-72.
10. National Cholesterol Education Program (NCEP) Expert Panel on Détection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 17 (106) 3143-421.
11. Hemmelgarn B, Blais L, Collet JP, et al. Automated databases and the need for fieldwork in pharmacoepidemiology. Pharmacoepidemiol Drug Safety 1994; 3: 275-82.
12. Chevalier C, Giral P, Chinaud F, Carzon M, Gartenlaub D, Blanchon B, et al. Adherence to national guidelines for lipid management and use of statins. Rev Epidemiol Santé Publique 2002; 50: 463-73.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines in cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
14. Marques-Vidal P, Bongard V, Arveiler D, Amouyel P, Ducimetiere P, Ferrieres J. Cost of cardiovascular risk factor prevention in France. Arch Mal Cœur 2002; 95: 275-81.
15. Hippisley-Cox J, Cater R, Pringle M, Coupland C. Cross-sectional survey of effectiveness of lipid lowering drugs in reducing cholesterol concentration in patients in 17 general practices. BMJ, 2003; 326: 689-93.
16. Heart Protection Study Heart Protection Study Collaborative Group. MRC / BHF Heart Protection Study of Cholesterol lowering simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet 1994; 334: 1383-9.
18. The long-term intervention with pravastatin in ischémie disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. For the Cholesterol and Recurrent Events Trial (CARE) investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
21. Shapiro S. The role of automated record linkage in the post-marketing surveillance of drug safety: a critique. Clin Pharmacol Ther 1989; 46: 371-86.
22. Cullen P, Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease, absolute levels or extent of lowering? Am J Cardiol 1997; 80: 1287-94.
23. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Therapeut 2001; 6: 129-35.